Bristol-Myers, J&J, Pharmacyclics deal

Bristol-Myers partnered with Pharmacyclics and Johnson & Johnson to evaluate Opdivo nivolumab in combination with Imbruvica ibrutinib in a Phase I/II trial to treat non-Hodgkin's lymphoma (NHL). Pharmacyclics and BMS declined to disclose financial terms or the trial's start date. J&J's Janssen Research & Development LLC subsidiary will conduct the trial. ...